Literature DB >> 29317141

Serum levels of osteopontin predict major adverse cardiovascular events in patients with severe carotid artery stenosis.

Federico Carbone1, Fabio Rigamonti2, Fabienne Burger3, Aline Roth3, Maria Bertolotto4, Giovanni Spinella5, Bianca Pane5, Domenico Palombo5, Aldo Pende4, Aldo Bonaventura4, Luca Liberale6, Alessandra Vecchié4, Franco Dallegri7, François Mach8, Fabrizio Montecucco9.   

Abstract

BACKGROUND: Inflammatory mediators in the blood stream and within plaques are key determinants in atherogenesis. Here, we investigated serum osteopontin (OPN) as a potential predictor of poor outcome in patients with severe carotid atherosclerosis.
METHODS: Carotid plaques and serum were collected from patients asymptomatic (n=185) or symptomatic (n=40) for ischemic stroke. Plaques were stained for lipids, smooth muscle cells, neutrophils, M1 and M2 macrophage subsets and matrix metallopropteinase-9 (MMP-9). Serum levels of OPN and interleukin-6 (IL-6) were determined by colorimetric enzyme-linked immunosorbent assays.
RESULTS: Symptomatic patients showed a two-fold increase in serum OPN levels. In both symptomatic and asymptomatic patients, OPN levels positively correlated with intraplaque count of neutrophils, total macrophages, and MMP-9 content. In asymptomatic patients, OPN levels also positively correlated with lipids and M1 macrophage subsets. Receiver operating characteristic curve analysis identified serum OPN concentration of 70ng/ml as the best cut-off value to predict major adverse cardiovascular events (MACEs). Patients with high OPN levels had more vulnerable plaque phenotype and reduced levels of HDL-cholesterol and IL-6 as compared to low OPN levels. Kaplan-Meier curve confirmed that patients with OPN levels >70ng/ml had more MACEs at a 24-month follow-up. In the multivariate survival analysis, OPN levels >70ng/ml predicted MACEs, independently of age, gender, and symptomatic status.
CONCLUSION: High circulating OPN levels were strongly correlated with vulnerability parameters within plaques and predict MACEs in patients with severe carotid artery stenosis. Although confirmation is needed from larger trials, OPN could be a promising clinical tool to assess atherosclerotic outcomes.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Inflammation; Macrophage; Osteopontin

Mesh:

Substances:

Year:  2018        PMID: 29317141     DOI: 10.1016/j.ijcard.2018.01.008

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  9 in total

1.  Osteopontin controls immunosuppression in the tumor microenvironment.

Authors:  Michael R Shurin
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

2.  Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer.

Authors:  Federico Carbone; Francesco Grossi; Aldo Bonaventura; Alessandra Vecchié; Silvia Minetti; Nicholas Bardi; Edoardo Elia; Anna Maria Ansaldo; Daniele Ferrara; Erika Rijavec; Maria Giovanna Dal Bello; Federica Biello; Giovanni Rossi; Marco Tagliamento; Angela Alama; Simona Coco; Paolo Spallarossa; Franco Dallegri; Carlo Genova; Fabrizio Montecucco
Journal:  Clin Exp Metastasis       Date:  2019-08-02       Impact factor: 5.150

3.  Decrease in inflammatory biomarker concentration by intervention with selenium and coenzyme Q10: a subanalysis of osteopontin, osteoprotergerin, TNFr1, TNFr2 and TWEAK.

Authors:  Urban Alehagen; Jan Alexander; Jan Aaseth; Anders Larsson
Journal:  J Inflamm (Lond)       Date:  2019-03-18       Impact factor: 4.981

4.  Association between carotid atheroma and cerebral cortex structure at age 73 years.

Authors:  Saud Alhusaini; Sherif Karama; Tuong-Vi Nguyen; Alexander Thiel; Boris C Bernhardt; Simon R Cox; Janie Corley; Adele Taylor; Alan C Evans; John M Star; Mark E Bastin; Joanna M Wardlaw; Ian J Deary; Simon Ducharme
Journal:  Ann Neurol       Date:  2018-10-05       Impact factor: 10.422

5.  Osteopontin as Candidate Biomarker of Coronary Disease despite Low Cardiovascular Risk: Insights from CAPIRE Study.

Authors:  Federico Carbone; Jennifer Meessen; Marco Magnoni; Daniele Andreini; Aldo Pietro Maggioni; Roberto Latini; Fabrizio Montecucco
Journal:  Cells       Date:  2022-02-15       Impact factor: 6.600

6.  Plasma osteopontin versus intima media thickness of the common carotid arteries in well-characterised patients with systemic lupus erythematosus.

Authors:  Lina Wirestam; Muna Saleh; Christina Svensson; Michele Compagno; Helene Zachrisson; Jonas Wetterö; Christopher Sjöwall
Journal:  Lupus       Date:  2021-05-06       Impact factor: 2.911

Review 7.  IL-1β and Statin Treatment in Patients with Myocardial Infarction and Diabetic Cardiomyopathy.

Authors:  Luca Liberale; Federico Carbone; Giovanni G Camici; Fabrizio Montecucco
Journal:  J Clin Med       Date:  2019-10-23       Impact factor: 4.241

Review 8.  Carotid artery stenosis and inflammatory biomarkers: the role of inflammation-induced immunological responses affecting the vascular systems.

Authors:  Tissa Wijeratne; Rohit Menon; Carmela Sales; Leila Karimi; Sheila Crewther
Journal:  Ann Transl Med       Date:  2020-10

9.  The TAXINOMISIS Project: A multidisciplinary approach for the development of a new risk stratification model for patients with asymptomatic carotid artery stenosis.

Authors:  Nathalie Timmerman; George Galyfos; Fragiska Sigala; Kalliopi Thanopoulou; Gert J de Borst; Lazar Davidovic; Hans-Henning Eckstein; Nenad Filipovic; Roberto Grugni; Michael Kallmayer; Dominique P V de Kleijn; Igor Koncar; Michalis D Mantzaris; Elisabeth Marchal; Miltiadis Matsagkas; Perica Mutavdzic; Domenico Palombo; Gerard Pasterkamp; Vassiliki T Potsika; Evangelos Andreakos; Dimitrios I Fotiadis
Journal:  Eur J Clin Invest       Date:  2020-10-02       Impact factor: 4.686

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.